VivoSim Announces $4 Million Public Offering

Got story updates? Submit your updates here. ›

VivoSim Labs, Inc., a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety testing, has announced the pricing of up to a $4 million public offering. The initial closing of $3 million is expected to occur on April 1, 2026, with an additional $1 million to be funded 30 days later, subject to certain conditions.

Why it matters

The public offering will provide VivoSim with additional capital to expand its preclinical safety testing services using human tissue models, which are expected to see increased adoption following a recent FDA announcement to refine animal testing requirements in favor of non-animal NAM methods.

The details

The public offering consists of the issuance and sale of common stock (or pre-funded warrants) at a subscription price of $1.140 per share and $1.139 per pre-funded warrant. The company will also issue common warrants to purchase up to 150% of the aggregate number of shares sold, with an exercise price of $1.710 per share. The offering is being led by a New York-based single family office, with Joseph Gunnar & Co., LLC serving as the exclusive placement agent.

• The initial closing of the offering is expected to occur on April 1, 2026.
• The additional $1 million tranche is expected to be funded 30 days after the initial closing, subject to certain conditions.

What’s next

The company will need to satisfy the closing conditions for the additional $1 million tranche, which is expected to occur 30 days after the initial closing.